← All trials
NCT01352637
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2011
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Cornell UniversityLead sponsor
- Emory UniversityOverall official - principal investigator
- University of Southern CaliforniaOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- Emory UniversityCollaborator
- University of Southern CaliforniaCollaborator
- National Intrepid Center of ExcellenceCollaborator
- Department of Veteran AffairsCollaborator
- Cornell UniversityReponsible party - principal investigator
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.